Claims for Patent: 10,086,089

Summary for Patent: 10,086,089

Title:	Systems and methods for nucleic acid expression in vivo
Abstract:	The present invention provides compositions, systems, kits, and methods for generating expression of one or more proteins and/or biologically active nucleic acid molecules in a subject (e.g., at therapeutic levels for extended periods required to produce therapeutic effects). In certain embodiments, systems and kits are provided that comprise a first composition comprising a first amount of polycationic structures, and a second composition comprising a therapeutically effective amount of expression vectors (e.g., non-viral expression vectors not associated with liposomes) that are CpG-free or CpG-reduced, where the expression vectors comprise a first nucleic acid sequence encoding: i) a first therapeutic protein or proteins, and/or ii) a first biologically active nucleic acid molecule or molecules.
Inventor(s):	Debs; Robert James (San Francisco, CA), Heath; Timothy D. (Madison, WI), Handumrongkul; Chakkrapong (Richmond, VA)
Assignee:	DNARx (San Francisco, CA)
Application Number:	15/268,000
Patent Claims:	1. A method of expressing a first therapeutic protein in a subject comprising: a) administering intravenously a first composition to a subject, wherein said first composition comprises a first amount of polycationic structures, and wherein said first composition is free, or essentially free, of nucleic acid molecules; and b) administering intravenously a second composition to said subject within about 300 minutes of administering said first composition, wherein said second composition comprises non-viral expression vectors, wherein said non-viral expression vectors are CpG-free or CpG-reduced, wherein said non-viral expression vectors each comprise the same first nucleic acid sequence encoding the same first therapeutic protein, wherein the ratio of said first amount of said polycationic structures to said non-viral expression vectors is 5:1 to 25:1, and wherein, as a result of said administering said first composition and said administering said second composition, said first therapeutic protein is expressed in said subject at a level of at least 50 pg/ml in serum for at least 7 consecutive days; and c) administering intravenously a drug agent, in said first and/or second composition, or present in a third composition, wherein said drug agent increases or decreases said expression level of said first therapeutic protein and/or the length of time of said expression compared to when said drug agent is not administered to said subject. 2. The method of claim 1, wherein said polycationic structures comprise empty liposomes. 3. The method of claim 2, wherein said empty liposomes present in said first composition have a z-average diameter of about 20-85 nm. 4. The method of claim 1, wherein: A) said ratio is 10:1 to 18:1; B) 2.0% to 6.0% of said first composition comprises dexamethasone or dexamethasone palmitate; and/or C) each of said non-viral expression vectors each comprise only a single expression cassette, wherein said single expression cassette comprises said first nucleic acid sequence encoding said first therapeutic protein and a second nucleic acid sequence encoding a second therapeutic protein. 5. The method of claim 1, wherein said drug agent is selected from colchicine, dexamethasone, dexamethasone palmitate, neutral lipids, valproic acid, theophylline, sildenafil, amlexanox, chloroquine, suberanilohydroxamic acid (SAHA), and L-arginine+sildenafil. 6. The method of claim 1, wherein said non-viral expression vectors each further comprise a regulating nucleic acid sequence, wherein said regulating nucleic acid sequence reduces the duration of expression of said first nucleic acid sequence that would occur in the absence of said regulating nucleic acid sequence. 7. The method of claim 6, wherein said regulating nucleic acid sequence is selected from the group consisting of: a promoter, an enhancer, a second nucleic acid sequence encoding a second protein, and a biologically active nucleic acid molecule. 8. The method of claim 1, wherein said first amount of polycationic structures in said first composition comprises a mixture of cationic lipid and neutral lipid that reduces the expression of said first therapeutic protein compared to such expression when only said cationic lipid is employed in said method. 9. The method of claim 1, wherein said first therapeutic protein is expressed at a level that is above 50 ng/ml in serum, and wherein said first therapeutic protein is expressed at said level in said subject for at least 7 consecutive days. 10. The method of claim 1, wherein said first therapeutic protein is selected from the group consisting of: human Granulocyte-colony stimulating factor (G-CSF), Rituximab, and human Factor IX. 11. A method of expressing a first therapeutic protein in a subject comprising: a) administering intravenously a first composition to a subject, wherein said first composition comprises a first amount of polycationic structures, and wherein said first composition is free, or essentially free, of nucleic acid molecules; and b) administering intravenously a second composition to said subject within about 300 minutes of administering said first composition, wherein said second composition comprises non-viral expression vectors, wherein said non-viral expression vectors are CpG-free or CpG-reduced, wherein said non-viral expression vectors each comprise the same first nucleic acid sequence encoding the same first therapeutic protein, c) administering intravenously dexamethasone, dexamethasone palmitate, and/or neutral lipids to said subject, either in said first and/or second composition, or present in a third composition, wherein, as a result of said administering said first composition, said administering said second composition, and said administering of said dexamethasone, dexamethasone palmitate, and/or neutral lipid, said first therapeutic protein is expressed in said subject at a level of at least 50 pg/ml in serum for at least 7 consecutive days, and d) administering intravenously a drug agent, in said first and/or second composition, or in said third composition, or present in a fourth composition, wherein said drug agent increases or decreases said expression level of said first therapeutic protein and/or the length of time of said expression compared to when said drug agent is not administered to said subject, and regulating vectors. 12. The method of claim 11, wherein said polycationic structures comprise empty liposomes, and wherein said empty liposomes present in said first composition have a z-average diameter of about 20-85 nm. 13. The method of claim 11, wherein each of said non-viral expression vectors each comprise only a single expression cassette, wherein said expression cassette comprises said first nucleic acid sequence encoding said first therapeutic protein and a second nucleic acid sequence encoding a second therapeutic protein. 14. The method of claim 11, wherein said dexamethasone palmitate is in said first composition, and wherein 2.0% to 6.0% of said first composition comprises said dexamethasone palmitate, and/or wherein said ratio is 5:1 to 25:1. 15. The method of claim 11, wherein said drug agent is selected from colchicine, dexamethasone, valproic acid, theophylline, sildenafil, amlexanox, chloroquine, suberanilohydroxamic acid (SAHA), and L-arginine+sildenafil. 16. The method of claim 11, wherein said non-viral expression vectors each further comprise a regulating nucleic acid sequence, wherein said regulating nucleic acid sequence reduces the duration of expression of said first nucleic acid sequence that would occur in the absence of said regulating nucleic acid sequence. 17. The method of claim 16, wherein said regulating nucleic acid sequence is selected from the group consisting of: a promoter, an enhancer, a second nucleic acid sequence encoding a second protein, and a biologically active nucleic acid molecule. 18. The method of claim 11, wherein said first therapeutic protein is expressed at a level that is above 50 ng/ml in serum, and wherein said first therapeutic protein is expressed at said level in said subject for at least 7 consecutive days. 19. The method of claim 11, wherein said first therapeutic protein is human Granulocyte-colony stimulating factor (G-CSF). 20. The method of claim 11, wherein said first therapeutic protein is Rituximab. 21. The method of claim 11, wherein said first therapeutic protein is human Factor IX.

Details for Patent 10,086,089

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2035-09-18
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2035-09-18